We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
A cystic fibrosis (CF) advocacy group has levied a formal complaint with the United Nations (UN), charging that Vertex Pharmaceuticals is violating the world body’s guidelines by unfairly pricing its CF drugs and not ensuring widespread equitable access. Read More
Distribution plans for the Pfizer-BioNTech COVID-19 vaccine in the U.S. remain an enormous question mark as an initial roll-out of mass vaccination gets under way in the UK. Read More
Beckton Dickinson (BD) has announced that it is investing $1.2 billion over four years toward strengthening its manufacturing capabilities for future pandemic responses and injectable drug and vaccine innovation. Read More
The decision was made “to respond to 340B program abuses arising from the excessive expansion of contract pharmacies,” a Novo Nordisk spokesperson said. Read More
Warnings of international crime targeting the yet-to-be-approved COVID-19 vaccines are getting louder, with the international police agency Interpol last week issuing an Orange Notice, which warns of an “imminent threat to public safety.” Read More
INO-4800 is currently undergoing a phase 2 study in the U.S., with the company having received a $71 million award from the Department of Defense to support clinical development of the vaccine and manufacture of its vaccine-administering smart device. Read More
Novo Nordisk has announced that effective Jan. 1, it will stop distributing discounted medications to community-based pharmacies of covered entity hospitals under the 340B Drug Pricing Program, joining other drugmakers who have taken similar steps to combat what they claim are duplicate discounts created under the program’s expansion to include contract pharmacies. Read More
A group of pharma industry investors is pressing several leading drugmakers to make their COVID-19 treatments and vaccines both affordable and accessible. Read More
Dolutegravir belongs to a class of drugs called HIV-integrase inhibitors that reduce the amount of HIV in the blood while boosting immune-cell production. Read More